124 related articles for article (PubMed ID: 36738846)
1. Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials.
Ferreira JP; Cleland JG; Girerd N; Rossignol P; Pellicori P; Cosmi F; Mariottoni B; González A; Diez J; Solomon SD; Claggett B; Pfeffer MA; Pitt B; Petutschnigg J; Pieske B; Edelmann F; Zannad F
Int J Cardiol; 2023 Apr; 377():86-88. PubMed ID: 36738846
[TBL] [Abstract][Full Text] [Related]
2. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
Ravassa S; Trippel T; Bach D; Bachran D; González A; López B; Wachter R; Hasenfuss G; Delles C; Dominiczak AF; Pieske B; Díez J; Edelmann F
Eur J Heart Fail; 2018 Sep; 20(9):1290-1299. PubMed ID: 29709099
[TBL] [Abstract][Full Text] [Related]
3. The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
Kobayashi M; Girerd N; Ferreira JP; Kevin D; Huttin O; González A; Bozec E; Clark AL; Cosmi F; Cuthbert J; Diez J; Edelmann F; Hazebroek M; Heymans S; Mariottoni B; Pellicori P; Petutschnigg J; Pieske B; Staessen JA; Verdonschot JAJ; Rossignol P; Cleland JGF; Zannad F
Eur J Heart Fail; 2022 Sep; 24(9):1559-1568. PubMed ID: 35703355
[TBL] [Abstract][Full Text] [Related]
4. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.
Ferreira JP; Cleland JG; Girerd N; Bozec E; Rossignol P; Pellicori P; Cosmi F; Mariottoni B; Solomon SD; Pitt B; Pfeffer MA; Shah AM; Petutschnigg J; Pieske B; Edelmann F; Zannad F
Eur J Heart Fail; 2023 Jan; 25(1):108-113. PubMed ID: 36303266
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials.
Xiang Y; Shi W; Li Z; Yang Y; Wang SY; Xiang R; Feng P; Wen L; Huang W
Medicine (Baltimore); 2019 Mar; 98(13):e14967. PubMed ID: 30921200
[TBL] [Abstract][Full Text] [Related]
6. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
[TBL] [Abstract][Full Text] [Related]
7. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
Cleland JGF; Ferreira JP; Mariottoni B; Pellicori P; Cuthbert J; Verdonschot JAJ; Petutschnigg J; Ahmed FZ; Cosmi F; Brunner La Rocca HP; Mamas MA; Clark AL; Edelmann F; Pieske B; Khan J; McDonald K; Rouet P; Staessen JA; Mujaj B; González A; Diez J; Hazebroek M; Heymans S; Latini R; Grojean S; Pizard A; Girerd N; Rossignol P; Collier TJ; Zannad F;
Eur Heart J; 2021 Feb; 42(6):684-696. PubMed ID: 33215209
[TBL] [Abstract][Full Text] [Related]
8. Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort.
Kobayashi M; Ferreira JP; Duarte K; Bresso E; Huttin O; Bozec E; Brunner La Rocca HP; Delles C; Clark AL; Edelmann F; González A; Heymans S; Pellicori P; Petutschnigg J; Verdonschot JAJ; Rossignol P; Cleland JGF; Zannad F; Girerd N;
Eur J Heart Fail; 2024 May; 26(5):1231-1241. PubMed ID: 38528728
[TBL] [Abstract][Full Text] [Related]
9. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial.
Pellicori P; Ferreira JP; Mariottoni B; Brunner-La Rocca HP; Ahmed FZ; Verdonschot J; Collier T; Cuthbert JJ; Petutschnigg J; Mujaj B; Girerd N; González A; Clark AL; Cosmi F; Staessen JA; Heymans S; Latini R; Rossignol P; Zannad F; Cleland JGF
Eur J Heart Fail; 2020 Sep; 22(9):1711-1723. PubMed ID: 31950604
[TBL] [Abstract][Full Text] [Related]
10. Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial).
Ferreira JP; Cleland JGF; Girerd N; Pellicori P; Hazebroek MR; Verdonschot J; Collier TJ; Petutschnigg J; Clark AL; Staessen JA; Heymans S; Rossignol P; Zannad F
Am J Cardiol; 2023 Mar; 191():39-42. PubMed ID: 36634548
[TBL] [Abstract][Full Text] [Related]
11. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Left Ventricular Reverse Remodeling and Outcomes by Circulating Collagen-Derived Peptides.
Ravassa S; Lupón J; López B; Codina P; Domingo M; Revuelta-López E; Moreno MU; San José G; Santiago-Vacas E; Cediel G; Roncal C; Díez J; Bayés-Genís A; González A
JACC Heart Fail; 2023 Jan; 11(1):58-72. PubMed ID: 36599551
[TBL] [Abstract][Full Text] [Related]
13. Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure.
Ferreira JP; Rossignol P; Pizard A; Machu JL; Collier T; Girerd N; Huby AC; Gonzalez A; Diez J; López B; Sattar N; Cleland JG; Sever PS; Zannad F
Heart; 2019 Feb; 105(4):307-314. PubMed ID: 30121630
[TBL] [Abstract][Full Text] [Related]
14. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
Trippel TD; Van Linthout S; Westermann D; Lindhorst R; Sandek A; Ernst S; Bobenko A; Kasner M; Spillmann F; González A; López B; Ravassa S; Pieske B; Paulus WJ; Díez J; Edelmann F; Tschöpe C
Eur J Heart Fail; 2018 Mar; 20(3):460-470. PubMed ID: 28891228
[TBL] [Abstract][Full Text] [Related]
15. Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis.
Lebedev DA; Lyasnikova EA; Vasilyeva EY; Babenko AY; Shlyakhto EV
J Diabetes Res; 2020; 2020():6976153. PubMed ID: 33224989
[TBL] [Abstract][Full Text] [Related]
16. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial.
Ravassa S; López B; Ferreira JP; Girerd N; Bozec E; Pellicori P; Mariottoni B; Cosmi F; Hazebroek M; Verdonschot JAJ; Cuthbert J; Petutschnigg J; Moreno MU; Heymans S; Staessen JA; Pieske B; Edelmann F; Clark AL; Cleland JGF; Zannad F; Díez J; González A;
Eur J Heart Fail; 2022 Feb; 24(2):321-331. PubMed ID: 34841615
[TBL] [Abstract][Full Text] [Related]
17. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
[TBL] [Abstract][Full Text] [Related]
18. Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial.
Yu YL; Siwy J; An DW; González A; Hansen T; Latosinska A; Pellicori P; Ravassa S; Mariottoni B; Verdonschot JA; Ahmed F; Petutschnigg J; Rossignol P; Heymans S; Cuthbert JJ; Girerd N; Clark AL; Verhamme P; Nawrot TS; Janssens S; Cleland JG; Zannad F; Diez J; Mischak H; Ferreira JP; Staessen JA;
Heart; 2024 May; ():. PubMed ID: 38729636
[TBL] [Abstract][Full Text] [Related]
19. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade.
Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; Marwick TH
Heart; 2013 Mar; 99(5):320-6. PubMed ID: 23343682
[TBL] [Abstract][Full Text] [Related]
20. Serum versus Imaging Biomarkers in Friedreich Ataxia to Indicate Left Ventricular Remodeling and Outcomes.
Mehta N; Chacko P; Jin J; Tran T; Prior TW; He X; Agarwal G; Raman SV
Tex Heart Inst J; 2016 Aug; 43(4):305-10. PubMed ID: 27547137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
